Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Short term Debt: 2017-2022

Historic Short term Debt for Cidara Therapeutics (CDTX) over the last 5 years, with Jun 2022 value amounting to $370,000.

  • Cidara Therapeutics' Short term Debt fell 92.30% to $370,000 in Q2 2022 from the same period last year, while for Jun 2022 it was $370,000, marking a year-over-year decrease of 92.30%. This contributed to the annual value of $2.6 million for FY2021, which is 63.11% down from last year.
  • As of Q2 2022, Cidara Therapeutics' Short term Debt stood at $370,000, which was down 75.02% from $1.5 million recorded in Q1 2022.
  • Cidara Therapeutics' 5-year Short term Debt high stood at $10.0 million for Q1 2020, and its period low was $370,000 during Q2 2022.
  • In the last 3 years, Cidara Therapeutics' Short term Debt had a median value of $5.4 million in 2021 and averaged $5.3 million.
  • As far as peak fluctuations go, Cidara Therapeutics' Short term Debt skyrocketed by 705.70% in 2018, and later plummeted by 92.30% in 2022.
  • Cidara Therapeutics' Short term Debt (Quarterly) stood at $9.9 million in 2018, then increased by 0.37% to $10.0 million in 2019, then fell by 29.52% to $7.0 million in 2020, then slumped by 63.11% to $2.6 million in 2021, then crashed by 92.30% to $370,000 in 2022.
  • Its last three reported values are $370,000 in Q2 2022, $1.5 million for Q1 2022, and $2.6 million during Q4 2021.